BIOMAT Database Logo BIOMAT Database Logo

[Course, therapy and diagnostic problems in diabetics with lactacidosis after biguanide treatment]. 1978

M Haslbeck, and P Wittmann, and W Bachmann, and H Mehnert

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007773 Lactates Salts or esters of LACTIC ACID containing the general formula CH3CHOHCOOR.
D003920 Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine
D005665 Furosemide A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY. Frusemide,Fursemide,Errolon,Frusemid,Furanthril,Furantral,Furosemide Monohydrochloride,Furosemide Monosodium Salt,Fusid,Lasix
D005947 Glucose A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement. Dextrose,Anhydrous Dextrose,D-Glucose,Glucose Monohydrate,Glucose, (DL)-Isomer,Glucose, (alpha-D)-Isomer,Glucose, (beta-D)-Isomer,D Glucose,Dextrose, Anhydrous,Monohydrate, Glucose
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001645 Biguanides Derivatives of biguanide (the structure formula HN(C(NH)NH2)2) that are primarily used as oral HYPOGLYCEMIC AGENTS for the treatment of DIABETES MELLITUS, TYPE 2 and PREDIABETES. Biguanide
D016883 Diabetic Ketoacidosis A life-threatening complication of diabetes mellitus, primarily of TYPE 1 DIABETES MELLITUS with severe INSULIN deficiency and extreme HYPERGLYCEMIA. It is characterized by KETOSIS; DEHYDRATION; and depressed consciousness leading to COMA. Acidosis, Diabetic,DKA Diabetic Ketoacidosis,Diabetic Acidosis,Diabetic Ketosis,Ketoacidosis, Diabetic,Ketosis, Diabetic,Acidoses, Diabetic,DKA Diabetic Ketoacidoses,Diabetic Acidoses,Diabetic Ketoacidoses,Diabetic Ketoacidosis, DKA,Diabetic Ketoses,Ketoacidoses, Diabetic,Ketoacidosis, DKA Diabetic,Ketoses, Diabetic

Related Publications

M Haslbeck, and P Wittmann, and W Bachmann, and H Mehnert
[Lactacidosis in biguanide therapy of diabetes mellitus].
November 1977, Deutsche medizinische Wochenschrift (1946),
M Haslbeck, and P Wittmann, and W Bachmann, and H Mehnert
[Biguanide-induced lactacidosis in diabetic patients].
February 1977, MMW, Munchener medizinische Wochenschrift,
M Haslbeck, and P Wittmann, and W Bachmann, and H Mehnert
[Lactacidosis in biguanide therapy: diagnosis and therapy. 4 cases compared to 179 cases in the world literature].
November 1978, Schweizerische medizinische Wochenschrift,
M Haslbeck, and P Wittmann, and W Bachmann, and H Mehnert
[Legal problems in biguanide therapy].
January 1978, Wiener medizinische Wochenschrift (1946),
M Haslbeck, and P Wittmann, and W Bachmann, and H Mehnert
The effect of biguanide treatment of body-weight in diabetics and non-diabetics.
May 1969, Postgraduate medical journal,
M Haslbeck, and P Wittmann, and W Bachmann, and H Mehnert
[Alteration of blood lactic acid levels in biguanide therapy in diabetics].
June 1985, Sichuan yi xue yuan xue bao = Acta Academiae Medicinae Sichuan,
M Haslbeck, and P Wittmann, and W Bachmann, and H Mehnert
[Biguanide treatment of diabetics. Effect on body weight--tolerance].
November 1969, Munchener medizinische Wochenschrift (1950),
M Haslbeck, and P Wittmann, and W Bachmann, and H Mehnert
[Treatment of diabetics by biguanide--its applicability with special reference to clinical observations].
October 1968, Nihon Naibunpi Gakkai zasshi,
M Haslbeck, and P Wittmann, and W Bachmann, and H Mehnert
Observations on the treatment of young diabetics with an oral drug (phenethyl-biguanide).
December 1959, Acta endocrinologica,
M Haslbeck, and P Wittmann, and W Bachmann, and H Mehnert
[Wegener's granulomatosis. Diagnostic problems and clinical course under immunosuppressive therapy].
August 1971, Schweizerische medizinische Wochenschrift,
Copied contents to your clipboard!